MAPT and Alzheimer disease: When comparing the two subgroups for each CSF biomarker, there were no significant differences, although trend significance was reached for p-tau (P = .092), which was higher in typical AD (91.6 ± 63.4 ng/L) compared with atypical AD (55.7 ± 15.3 ng/L; Fig. 2).